Skip To Main Content
Shanying Road on Muck Rack

Shanying Road

As seen in: Diabetes Research and Clinical Practice
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shanying

Contact Shanying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

SGLT2 inhibitors and the risk of incident chronic kidney disease in type 2 diabetes: a nationwide emulated target trial in Taiwan

|
By Fu-Shun Yen, Shanying Road, Gueishan District
| Diabetes Research and Clinical Practice Verified
Keywords Macroalbuminuria Dialysis Acute kidney injury Cardiovascular events All-cause mortality Abbreviations T2D (type 2 diabetes) CKD (chronic kidney disease) eGFR (estimated glomerular filtration rate) UACR (urinary albumin-to-creatinine ratio) UPCR (urine protein-creatinine ratio) SGLT2 (sodium-glucose cotransporter 2) ACEI (angiotensin-converting enzyme inhibitors) ARB (angiotensin receptor blocker) GLP-1 RA (glucagon-like peptide-1 receptor agonists) HbA1c (hemoglobin A1C) Get full...
Open in Who Shared Issue with article?

Comparative outcomes of adding SGLT2 inhibitors versus incretin-based therapies to insulin in type 2 diabetes

|
By Fu-Shun Yen, Yen’s Clinic, Shanying Road, Gueishan District
| Diabetes Research and Clinical Practice Verified
Keywords Coronary artery disease Stroke Heart failure End-stage kidney disease Sight-threatening retinopathy Amputation All-cause mortality Abbreviations T2D (type 2 diabetes) SGLT2 (sodium-glucose cotransporter-2) GLP-1RA (glucagon-like peptide-1 receptor agonist) DPP-4 (dipeptidyl peptidase-4) CAD (coronary artery disease) MACE (major adverse cardiovascular events) ESKD (end-stage kidney disease) OADs (oral antidiabetic drugs) Get full text access Log in, subscribe or purchase for full access.
Open in Who Shared Issue with article?

Outcomes of second-line oral antidiabetic drugs in persons with young-onset type 2 diabetes

|
By Fu-Shun Yen, Yen’s Clinic, Shanying Road, Gueishan District
| Diabetes Research and Clinical Practice Verified
Highlights • Add-on DPP-4 inhibitors is associated with lower risks of all-cause hospitalization. • Add-on DPP-4 inhibitors is associated with lower risks of all-cause mortality. • DPP-4 inhibitors seem to be a suitable second-line OAD for patients for YOD. Abstract Aim People with young-onset diabetes (YOD) exhibit a higher risk of morbidity and mortality than those with late-onset diabetes. Few studies have explored the preferred management of diabetes in such patients.
Open in Who Shared Issue with article?
See all 3 articles